107 related articles for article (PubMed ID: 1388697)
1. Human brain phenolsulfotransferase. Regional distribution in Parkinson's disease.
Baran H; Jellinger K
J Neural Transm Park Dis Dement Sect; 1992; 4():267-76. PubMed ID: 1388697
[TBL] [Abstract][Full Text] [Related]
2. Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.
Ciesielska A; Samaranch L; San Sebastian W; Dickson DW; Goldman S; Forsayeth J; Bankiewicz KS
PLoS One; 2017; 12(2):e0169965. PubMed ID: 28166239
[TBL] [Abstract][Full Text] [Related]
3. Effect of probenecid on rat brain phenolsulfotransferase activity using dopamine as substrate.
Kao GY; Elchisak MA
Pharmacology; 1987; 34(5):259-63. PubMed ID: 3475732
[TBL] [Abstract][Full Text] [Related]
4. Circadian rhythms in catecholamine metabolites and cyclic nucleotide production.
Kafka MS; Benedito MA; Roth RH; Steele LK; Wolfe WW; Catravas GN
Chronobiol Int; 1986; 3(2):101-15. PubMed ID: 2824067
[TBL] [Abstract][Full Text] [Related]
5. Human brain phenol sulfotransferase: biochemical properties and regional localization.
Young WF; Okazaki H; Laws ER; Weinshilboum RM
J Neurochem; 1984 Sep; 43(3):706-15. PubMed ID: 6589361
[TBL] [Abstract][Full Text] [Related]
6. Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
Tong J; Rathitharan G; Meyer JH; Furukawa Y; Ang LC; Boileau I; Guttman M; Hornykiewicz O; Kish SJ
Brain; 2017 Sep; 140(9):2460-2474. PubMed ID: 29050386
[TBL] [Abstract][Full Text] [Related]
7. Dopamine in thelimbic regions of the human brain: normal and abnormal.
Farley IJ; Price KS; Hornykiewicz O
Adv Biochem Psychopharmacol; 1977; 16():57-64. PubMed ID: 883559
[TBL] [Abstract][Full Text] [Related]
8. Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms?
Jellinger KA
J Neural Transm Suppl; 1999; 56():1-29. PubMed ID: 10370901
[TBL] [Abstract][Full Text] [Related]
9. Relatively high levels of dopamine in nucleus accumbens of levodopa treated patients with Parkinson's disease.
Goldstein M; Lieberman A; Pearson J
J Neural Transm; 1982; 54(1-2):129-34. PubMed ID: 6125563
[TBL] [Abstract][Full Text] [Related]
10. Substance P immunoreactivity in the post-mortem parkinsonian brain.
Tenovuo O; Rinne UK; Viljanen MK
Brain Res; 1984 Jun; 303(1):113-6. PubMed ID: 6203617
[TBL] [Abstract][Full Text] [Related]
11. Contribution of sulfate conjugation, deamination, and O-methylation to metabolism of dopamine and norepinephrine in human brain.
Rivett AJ; Eddy BJ; Roth JA
J Neurochem; 1982 Oct; 39(4):1009-16. PubMed ID: 6956674
[TBL] [Abstract][Full Text] [Related]
12. Relationship between catechol-O-methyltransferase and phenolsulfotransferase in the metabolism of dopamine in the rat brain.
Buu NT
J Neurochem; 1985 Nov; 45(5):1612-9. PubMed ID: 3930664
[TBL] [Abstract][Full Text] [Related]
13. Alterations in [3H]spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in the Shy-Drager syndrome and Parkinson's disease.
Quik M; Spokes EG; Mackay AV; Bannister R
J Neurol Sci; 1979 Nov; 43(3):429-37. PubMed ID: 521836
[TBL] [Abstract][Full Text] [Related]
14. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain.
Madras BK; Gracz LM; Fahey MA; Elmaleh D; Meltzer PC; Liang AY; Stopa EG; Babich J; Fischman AJ
Synapse; 1998 Jun; 29(2):116-27. PubMed ID: 9593102
[TBL] [Abstract][Full Text] [Related]
15. Brain enkephalin receptors in Parkinson's disease.
Rinne UK; Rinne JK; Rinne JO; Laakso K; Tenovuo O; Lönnberg P; Koskinen V
J Neural Transm Suppl; 1983; 19():163-71. PubMed ID: 6321647
[TBL] [Abstract][Full Text] [Related]
16. Regional distribution of vasoactive intestinal peptide in brains from normal and parkinsonian subjects.
Jégou S; Javoy-Agid F; Delbende C; Tranchand-Bunel D; Coy DH; Agid Y; Vaudry H
Peptides; 1988; 9(4):787-93. PubMed ID: 3226955
[TBL] [Abstract][Full Text] [Related]
17. Nerve growth factor receptor immunoreactivity within the nucleus basalis (Ch4) in Parkinson's disease: reduced cell numbers and co-localization with cholinergic neurons.
Mufson EJ; Presley LN; Kordower JH
Brain Res; 1991 Jan; 539(1):19-30. PubMed ID: 1849779
[TBL] [Abstract][Full Text] [Related]
18. Distinct gradients of various neurotransmitter markers in caudate nucleus and putamen of the human brain.
Hörtnagl H; Pifl C; Hörtnagl E; Reiner A; Sperk G
J Neurochem; 2020 Mar; 152(6):650-662. PubMed ID: 31608979
[TBL] [Abstract][Full Text] [Related]
19. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
Riederer P; Youdim MB
J Neurochem; 1986 May; 46(5):1359-65. PubMed ID: 2420928
[TBL] [Abstract][Full Text] [Related]
20. Imaging in Parkinson's disease: the role of monoamines in behavior.
Brooks DJ; Piccini P
Biol Psychiatry; 2006 May; 59(10):908-18. PubMed ID: 16581032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
